Pediatrix Medical Group Reports General Counsel Transition; New GC Appointed
$MD · Pediatrix Medical Group, Inc.Research Summary
AI-generated summary of this SEC filing
Pediatrix Medical Group Reports General Counsel Transition; New GC Appointed
What Happened
Pediatrix Medical Group, Inc. announced that Mary Ann E. Moore, Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, will transition from the company and leave effective October 31, 2026. On July 21, 2026 Ms. Moore and PMG Services, Inc. (a wholly-owned subsidiary) entered into a Separation Agreement; her departure is treated as a termination without cause under her Second Amended and Restated Employment Agreement and she will receive the contractual benefits specified in that agreement. The company also disclosed the appointment of David Haddock as Executive Vice President, General Counsel and Secretary.
Key Details
- Filing date: Form 8-K filed July 24, 2026.
- Transition timeline: Company and Ms. Moore agreed May 1, 2026 on a transition; Separation Agreement executed July 21, 2026; Ms. Moore will serve in an advisory role until her departure on October 31, 2026.
- Employment status: The separation is characterized as a termination without cause under Ms. Moore’s Second Amended and Restated Employment Agreement; the agreement specifies the benefits she will receive (amounts/details not disclosed in the 8-K).
- New appointment: David Haddock has been appointed Executive Vice President, General Counsel and Secretary (disclosed under Regulation FD).
Why It Matters
Executive changes in the company’s legal and corporate governance leadership can affect continuity in compliance, contract management, litigation oversight and strategic legal matters. The filing indicates an orderly transition with an interim advisory period and a named successor, which reduces uncertainty about immediate leadership gaps. The 8-K does not disclose severance amounts or other financial details beyond stating that Ms. Moore will receive the contractually specified benefits. Investors should note the leadership change and monitor future disclosures for any additional details about succession, compensation or impacts on operations.